Phosphoric Acid

Phosphoric Acid

SCHEMBL232957

O.O.O.O.O.O.O.O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.43
SLC34A1 Q06495 1/20 0.42
KDM4E B2RXH2 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
CA1 P00915 2/20 0.33
CA4 P22748 2/20 0.33
CA5A P35218 2/20 0.33
CA5B Q9Y2D0 2/20 0.33
BLM P54132 1/20 0.32
PMP22 Q01453 1/20 0.32
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
ALOX12 P18054 1/20 0.32
NFKB1 P19838 1/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL122808 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL1396195 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL735586 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL1076271 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL156385 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL1804580 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL734680 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL736397 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL2020039 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL14760076 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3341409-B1 BIOPHARMACEUTICAL COMPOSITIONS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2026-02-25 EP claimed
EP-3347043-B1 PROCESS FOR PREPARING AN ATTENUATED TETRAVALENT DENGUE VACCINE FUND BUTANTAN (BR) 2026-01-07 EP claimed
US-20250242115-A1 DISPENSING DEVICE AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RHINITIS GLENMARK SPECIALTY S.A. (CH) 2025-07-31 US claimed
US-12303635-B2 Dispensing device and pharmaceutical composition for the treatment of rhinitis GLENMARK SPECIALTY S.A. (CH) 2025-05-20 US claimed
CN-119264879-A Inorganic salt phase change material and preparation method and application thereof 广东美的暖通设备有限公司 2025-01-07 CN claimed
EP-3419651-B1 IMPROVED NAGLU FUSION PROTEIN FORMULATION BIOMARIN PHARM INC (US) 2023-10-25 EP claimed
EP-3294345-B1 TPP1 FORMULATIONS AND METHODS FOR TREATING CLN2 DISEASE BIOMARIN PHARM INC (US) 2023-10-18 EP claimed
US-20230285689-A1 DISPENSING DEVICE AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RHINITIS GLENMARK SPECIALTY S.A. (CH) 2023-09-14 US claimed
CN-111787954-B Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine 格兰马克专业公司 2023-09-05 CN claimed
CN-107072121-B Quick soaking energy storage heat radiation structure for eliminating heat wave crest 平湖阿莱德实业有限公司 2023-07-04 CN claimed
US-20130245124-A1 PRESERVATIVE FREE BIMATOPROST SOLUTIONS ALLERGAN, INC. (US) 2013-09-19 US claimed
EP-2598117-A2 PRESERVATIVE FREE BIMATOPROST SOLUTIONS Allergan, Inc. (US) 2013-06-05 EP claimed
US-20120213700-A1 COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN NAVIDEA BIOPHARMACEUTICALS, INC. (US) 2012-08-23 US claimed
WO-2012015996-A2 PRESERVATIVE FREE BIMATOPROST SOLUTIONS ALLERGAN, INC. (US) 2012-02-02 WO claimed
EP-1712245-B1 Calcium phosphate cement HOWMEDICA OSTEONICS CORP (US) 2012-02-01 EP claimed
US-20100196272-A1 COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN NEOPROBE CORPORATION (US) 2010-08-05 US claimed
WO-2010087959-A1 COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN NEOPROBE CORPORATION (US) 2010-08-05 WO claimed
US-20090131537-A1 Wound healing compositions WILLE JR JOHN JACOB 2009-05-21 US claimed
WO-2006029463-A1 HEAT EXCHANGER IMPROVEMENTS INFORM ENERGY PTY LTD (AU) 2006-03-23 WO claimed
EP-0799046-B1 STABLE SOLUTIONS OF 2-CHLORO-2'-DEOXYADENOSINE ORTHO PHARMA CORP (US) 2002-06-05 EP claimed